{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:07:43Z","timestamp":1794283663719,"version":"4.9.0"},"reference-count":53,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.urolonc.2023.11.017","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T23:34:37Z","timestamp":1702596877000},"page":"160.e11-160.e23","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"42","author":[{"given":"Toni","family":"Febriyanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fajar","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2111-9839","authenticated-orcid":false,"given":"Wynne","family":"Wijaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Oey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7512-2112","authenticated-orcid":false,"given":"Daniel Martin","family":"Simadibrata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2023.11.017_bib0001","first-page":"15","article-title":"Epidemiology of Bladder Cancer","volume":"8","author":"Saginala","year":"2020","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0002","first-page":"11536","article-title":"Advanced\/metastatic bladder cancer: current status and future directions","volume":"24","author":"Facchini","year":"2020","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0003","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0004","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","article-title":"Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy","volume":"29","author":"Galsky","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0005","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0006","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.21037\/apm-22-1350","article-title":"Immunotherapy for advanced urothelial carcinoma (UC): Rational and current evidence","volume":"12","author":"Uccello","year":"2023","journal-title":"Ann Palliat Med"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0007","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101925","article-title":"The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma","volume":"82","author":"Powles","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2021.103374","article-title":"TMB or not TMB as a biomarker: That is the question","volume":"163","author":"Addeo","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0010","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197295","article-title":"Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients","volume":"21","author":"Sabbatino","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0011","doi-asserted-by":"crossref","first-page":"929","DOI":"10.5306\/wjco.v13.i11.929","article-title":"Gut microbiota diversity and composition in predicting immunotherapy response and immunotherapy-related colitis in melanoma patients: A systematic review","volume":"13","author":"Oey","year":"2022","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0012","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-022-01273-9","article-title":"Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies","volume":"15","author":"Lu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0013","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.3389\/fimmu.2018.03059","article-title":"Dendritic Cells and CD8 T Cell Immunity in Tumor Microenvironment","volume":"9","author":"Fu","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0014","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1126\/science.aad1329","article-title":"Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota","volume":"350","author":"V\u00e9tizou","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0015","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1126\/science.aac4255","article-title":"Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy","volume":"350","author":"Sivan","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0016","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0017","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0018","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/s41586-019-0878-z","article-title":"A defined commensal consortium elicits CD8 T cells and anti-cancer immunity","volume":"565","author":"Tanoue","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0019","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0020","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/COC.0000000000000813","article-title":"Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment","volume":"44","author":"Khan","year":"2021","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0021","first-page":"e16829","article-title":"Influence of Microbiome and Antibiotics on the Efficacy of Immune Checkpoint Inhibitors","volume":"13","author":"Patel","year":"2021","journal-title":"Cureus"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0022","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/annonc\/mdz206","article-title":"The negative impact of antibiotics on outcomes in cancer patients treated with immunotherapy: a new independent prognostic factor?","volume":"30","author":"Elkrief","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106876","article-title":"Antibiotic administration shortly before or after immunotherapy initiation is correlated with poor prognosis in solid cancer patients: An up-to-date systematic review and meta-analysis","volume":"88","author":"Yang","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0024","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijid.2021.03.063","article-title":"Use of antibiotics is associated with worse clinical outcomes in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"106","author":"Tsikala-Vafea","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1075593","article-title":"A systematic review and meta-analysis evaluating the impact of antibiotic use on the clinical outcomes of cancer patients treated with immune checkpoint inhibitors","volume":"13","author":"Crespin","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0026","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0027","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0028","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0029","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.eururo.2020.06.061","article-title":"Concomitant Antibiotic Use and Survival in Urothelial Carcinoma Treated with Atezolizumab","volume":"78","author":"Hopkins","year":"2020","journal-title":"European Urology"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0030","doi-asserted-by":"crossref","first-page":"346.e1","DOI":"10.1016\/j.urolonc.2022.02.020","article-title":"Effectiveness of pembrolizumab in patients with urothelial carcinoma receiving proton pump inhibitors","volume":"40","author":"Fukuokaya","year":"2022","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0031","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1097\/JU.0000000000002062.15","article-title":"MP41-15 proton pump inhibitor use is a negative prognostic factor for metastatic urothelial carcinoma progression in pembrolizumab-treated patients","volume":"206","author":"Iida","year":"2021","journal-title":"Journal of Urology"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0032","doi-asserted-by":"crossref","first-page":"834.e21","DOI":"10.1016\/j.urolonc.2021.05.033","article-title":"Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma","volume":"39","author":"Ishiyama","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0033","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.21873\/anticanres.15638","article-title":"Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma","volume":"42","author":"Tomisaki","year":"2022","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0034","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0035","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1200\/JCO.2019.37.7_suppl.435","article-title":"Impact of concurrent medications on outcomes with PD1\/PD-L1 inhibitors for metastatic urothelial carcinoma","volume":"37","author":"Agarwal","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0036","doi-asserted-by":"crossref","first-page":"S597","DOI":"10.1016\/j.annonc.2020.08.850","article-title":"778P concomitant antibiotic use and its effect on immune-checkpoint inhibitor efficacy in patients with advanced urothelial carcinoma","volume":"31","author":"Khan","year":"2020","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0037","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/bco2.118","article-title":"Prognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma","volume":"3","author":"Okuyama","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100090","article-title":"Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study","volume":"6","author":"Ruiz-Ba\u00f1obre","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0039","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1200\/JCO.2019.37.15_suppl.4557","article-title":"Impact of antibiotic use on clinical outcomes in patients with urothelial cancer receiving a programmed death protein 1 or programmed death ligand 1 (anti-PD-1\/L1) antibody","volume":"37","author":"Weinstock","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0040","first-page":"e1128","article-title":"PD44-10 ASSOCIATION BETWEEN ANTIBIOTIC AND TREATMENT EFFICACY IN UROTHELIAL CARCINOMA PATIENTS RECEIVING IMMUNOTHERAPY OR CHEMOTHERAPY","volume":"209","author":"Braun","year":"2023","journal-title":"The Journal of Urology"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0041","doi-asserted-by":"crossref","first-page":"S1603","DOI":"10.1016\/j.annonc.2022.10.444","article-title":"413P Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database","volume":"33","author":"Hong","year":"2022","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0042","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.imlet.2018.02.001","article-title":"Modulation of dendritic cell by pathogen antigens: Where do we stand?","volume":"196","author":"Peron","year":"2018","journal-title":"Immunol Lett"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0043","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s10620-020-06111-x","article-title":"Gut Microbiome Modulates Response to Cancer Immunotherapy","volume":"65","author":"Khan","year":"2020","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0044","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s40425-019-0574-4","article-title":"Exploring the emerging role of the microbiome in cancer immunotherapy","volume":"7","author":"Fessler","year":"2019","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0045","doi-asserted-by":"crossref","first-page":"395","DOI":"10.3747\/co.26.5177","article-title":"Impact of the gut microbiome on immune checkpoint inhibitor efficacy-a systematic review","volume":"26","author":"Pierrard","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0046","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.neo.2017.08.004","article-title":"Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients","volume":"19","author":"Frankel","year":"2017","journal-title":"Neoplasia"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0047","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/annonc\/mdx108","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"28","author":"Chaput","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0048","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1126\/science.aao3290","article-title":"The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients","volume":"359","author":"Matson","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0049","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-019-0495-2","article-title":"Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study","volume":"25","author":"Depommier","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.2895","article-title":"Association of Short-Chain Fatty Acids in the Gut Microbiome With Clinical Response to Treatment With Nivolumab or Pembrolizumab in Patients With Solid Cancer Tumors","volume":"3","author":"Nomura","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0051","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1001\/jamaoncol.2019.2785","article-title":"Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer","volume":"5","author":"Pinato","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0052","doi-asserted-by":"crossref","first-page":"S389","DOI":"10.1016\/j.jtho.2018.08.395","article-title":"MA10. 01 antibiotic use and PD-1 inhibitors: Shorter survival in lung cancer, especially when given intravenously. Type of infection also matters","volume":"13","author":"Mielgo-Rubio","year":"2018","journal-title":"Journal of Thoracic Oncology"},{"key":"10.1016\/j.urolonc.2023.11.017_bib0053","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1634\/theoncologist.2019-0160","article-title":"Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer","volume":"25","author":"Tinsley","year":"2020","journal-title":"Oncologist"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923004155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923004155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T22:42:35Z","timestamp":1712875355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923004155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S1078143923004155"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.017","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibiotic use reduces the efficacy of immune checkpoint inhibitors in patients with urothelial carcinoma: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}